Human Monoclonal Antibodies against Emerging Viruses

Dimiter Dimitrov of National Cancer Institute, NIH joined us for Americas Antibody Congress 2016 to discuss ‘human monoclonal antibodies against emerging viruses’. In this presentation, learn about the correlation between human monoclonal antibodies and emerging viruses. Download this presentation to understand more about: Identification of mAbs by phage and yeast display from libraries of native human antibody fragments Libraries of …

Developing a cell-penetrating antibody into a clinic-ready platform with widespread utility as a functional intra-cellular delivery vehicle

Dr. Dustin Armstrong of Valerion Therapeutics, LLC joined us for Americas Antibody Congress 2016 to discuss ‘developing a cell-penetrating antibody into a clinic-ready platform with widespread utility as a functional intra-cellular delivery vehicle‘ In this presentation, learn about VAL-1205: a functional intracellular delivery vehicle . Download this presentation to understand more about: Platform considerations Cell-free and in vitro data Functional …

Exciting developments in immunotherapy concerning CAR-T, CAR-T for solid tumours and immune checkpoint inhibitors

Immunotherapy has been around since the eighteenth century, when it was noticed that patients suffering with cancer would sometimes go into remission after suffering from a fever. However it wasn’t until the 1890s that someone started to carry out scientific research on this. William Coley carried out experiments where streptococcal cultures were injected into cancer patients, and regression was seen …

HELM

Making Open Source Collaboration Work

Over the past few years the biopharmaceutical industry has deployed an arsenal of increasingly complex biomolecular entities in their search for effective therapeutic agents. Portfolios that were once comprised mainly of small molecules and antibodies have expanded to include modalities like antibody-drug conjugates (ADCs); proteins, peptides and antibodies with synthetic, unnatural amino acids; oligonucleotides with unnatural bases, etc. Investigators at …

HELM

HELM for Antibody Registration

Roche’s Pharmaceutical Research and Early Development (pRED) informatics team has adopted the Pistoia Alliance’s Hierarchical Editing Language for Macromolecules (HELM) as a fundamental building block of their antibody registration tool. As a result, the HELM notation and the HELM Antibody Editor (HAbE) are being rolled out throughout Roche’s bio-therapeutics group (“Large Molecule Research”) to improve the speed, accuracy and effectiveness …

The World Immunotherapy Congress speaks to Renier Brentjens, Memorial Sloane Kettering

Earlier this year we got in touch with Renier Brentjens, Memorial Sloane Kettering, to talk about the industry ahead of his presentation at the World Immunotherapy congress taking place 14-16th November. 1) What do you think has been the biggest achievement within the immunotherapy sector in the last 12 months? I believe that the biggest achievement is a tie between …

Juno Therapeutics CAR-T JCAR015 trial – how you can meet them this November

In early July 2016, Juno Therapeutics stock value plummeted by an unprecedented 27% after three patients died in a clinical trial testing their lead cancer therapy. After this, US regulators put this trial on pause, causing questions to be asked about the safety of the new approaches to battling cancer. The trial in question was being tested on adults with …

European Antibody Congress Speaker Interviews

The European Antibody Congress will be gracing the Basel Conference Centre once again this November to bring a twelfth year of top speakers, expert discussions and dedicated networking sessions. This year we will be covering armed antibodies, bispecifics, early discovery and analytics, CMC and developability, regulations and intellectual property, clinical development and novel uses for antibodies. After 11 previously successful …

Merck's Commitment to

“Merck’s Commitment to Infectious Diseases: The Commercialization Challenges of New Antibiotics”

Brian Woolhoouse, VP and General Manager, Hospital Acute Care at Merck joined us for World Anti-Microbial Resistance Congress USA 2015 to discuss ‘Merck’s Commitment to Infectious Diseases: The Commercialization Challenges of New Antibiotics”. In this presentation, learn about Merck’s commitment to innovation and leadership in infectious diseases. Download the presentation to understand more about: How Merck is actively addressing the …

Development of ceftazidime-avibactam...navigating an evolving regulatory environment

“Clinical development of ceftazidime-avibactam…Navigating an evolving regulatory environment”

David Melnick, M.D., Vice President Clinical Development, Anti-Infectives at Allergan Pharmaceuticals joined us for World Anti-Microbial Resistance Congress USA 2015 to discuss “navigating an evolving regulatory environment”. In this presentation, learn about some of the effects of the changing regulatory environment on the clinical development of ceftazidime-avibactam. Download the presentation to understand more about: Avycaz Carbapenem-resistant Enterobacteriaceae (CRE) Well-defined PK/PD …